[
  {
    "text": "Development Agreement",
    "bbox": [
      572,
      97,
      762,
      109
    ],
    "label": 1,
    "category": "Document Name"
  },
  {
    "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
    "bbox": [
      112,
      144,
      1000,
      157
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\".",
    "bbox": [
      112,
      161,
      762,
      173
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
    "bbox": [
      180,
      113,
      1000,
      125
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
    "bbox": [
      112,
      144,
      1000,
      157
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
    "bbox": [
      180,
      113,
      1000,
      125
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "Pharmaceuticals, Inc. (\"CNS'), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and.",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
    "bbox": [
      112,
      144,
      1000,
      157
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
    "bbox": [
      180,
      113,
      1000,
      125
    ],
    "label": 3,
    "category": "Agreement Date"
  },
  {
    "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
    "bbox": [
      180,
      113,
      1000,
      125
    ],
    "label": 4,
    "category": "Effective Date"
  },
  {
    "text": "Exhibit 10.1.",
    "bbox": [
      111,
      81,
      196,
      92
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Development Agreement",
    "bbox": [
      572,
      97,
      762,
      109
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
    "bbox": [
      180,
      113,
      1000,
      125
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Pharmaceuticals, Inc. (\"CNS'), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and.",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
    "bbox": [
      112,
      144,
      1000,
      157
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\".",
    "bbox": [
      112,
      161,
      762,
      173
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "RECITALS",
    "bbox": [
      624,
      177,
      710,
      188
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (\"MBI) (the \"Sublicense",
    "bbox": [
      180,
      192,
      1000,
      204
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Agreement') to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use in",
    "bbox": [
      112,
      209,
      1000,
      221
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "certain territories;",
    "bbox": [
      111,
      226,
      243,
      236
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; and",
    "bbox": [
      179,
      241,
      968,
      253
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights..",
    "bbox": [
      180,
      257,
      1000,
      269
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration,",
    "bbox": [
      177,
      273,
      1000,
      285
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows:.",
    "bbox": [
      112,
      289,
      875,
      301
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      621,
      304,
      712,
      315
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      321,
      723,
      332
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.1 \"Approval Achievement Date\"' means the earlier of the: (i) date on which WPD receives marketing approval for a Development Product",
    "bbox": [
      179,
      336,
      1000,
      349
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Development Fees hereunder of $1.0 million..",
    "bbox": [
      112,
      369,
      443,
      380
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.2 \"Business Day\"' means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized or",
    "bbox": [
      179,
      384,
      1000,
      397
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "required to be closed in New York City, NY..",
    "bbox": [
      111,
      400,
      432,
      412
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.3 \"Calendar Quarter\"' means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31.",
    "bbox": [
      179,
      417,
      1000,
      428
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.4 \"Confidential Information\"' includes: (1) all information contained in documents marked \"confidential\" and disclosed by one Party (the",
    "bbox": [
      179,
      432,
      1000,
      445
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "\"disclosing party\") to the other Party (the \"recipient party\") pursuant to this Agreement; (2) orally disclosed information which is disclosed by the",
    "bbox": [
      112,
      448,
      1000,
      461
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "disclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as \"confidential\" and delivered to the recipient",
    "bbox": [
      111,
      464,
      1000,
      477
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "party; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person would",
    "bbox": [
      111,
      480,
      1000,
      493
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "treat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not the",
    "bbox": [
      111,
      497,
      1000,
      509
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "information is marked as \"confidential.\" Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNS",
    "bbox": [
      111,
      512,
      1000,
      525
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "determines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof..",
    "bbox": [
      112,
      529,
      1000,
      541
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.5 \"Development Fee'\" means 50% of the Net Sales for any Development Products in the Development Territory..",
    "bbox": [
      179,
      543,
      1000,
      557
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.6 \"Development Products\" means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drug",
    "bbox": [
      180,
      561,
      1000,
      573
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "products for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for the",
    "bbox": [
      112,
      577,
      1000,
      589
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "treatment of any viral infection in humans that is licensed between WPD and MBI after this date..",
    "bbox": [
      112,
      593,
      837,
      604
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.7 \"Development Territory\"' means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense.",
    "bbox": [
      178,
      608,
      1000,
      621
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Agreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland..",
    "bbox": [
      114,
      625,
      1000,
      637
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1",
    "bbox": [
      661,
      648,
      673,
      658
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020",
    "bbox": [
      133,
      1000,
      572,
      1000
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Exhibit 10.1.",
    "bbox": [
      111,
      81,
      196,
      92
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Development Agreement",
    "bbox": [
      572,
      97,
      762,
      109
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
    "bbox": [
      180,
      113,
      1000,
      125
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Pharmaceuticals, Inc. (\"CNS'), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and.",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
    "bbox": [
      112,
      144,
      1000,
      157
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\".",
    "bbox": [
      112,
      161,
      762,
      173
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "RECITALS",
    "bbox": [
      624,
      177,
      710,
      188
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (\"MBI) (the \"Sublicense",
    "bbox": [
      180,
      192,
      1000,
      204
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Agreement') to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use in",
    "bbox": [
      112,
      209,
      1000,
      221
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "certain territories;",
    "bbox": [
      111,
      226,
      243,
      236
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; and",
    "bbox": [
      179,
      241,
      968,
      253
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights..",
    "bbox": [
      180,
      257,
      1000,
      269
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration,",
    "bbox": [
      177,
      273,
      1000,
      285
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows:.",
    "bbox": [
      112,
      289,
      875,
      301
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      621,
      304,
      712,
      315
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      321,
      723,
      332
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.1 \"Approval Achievement Date\"' means the earlier of the: (i) date on which WPD receives marketing approval for a Development Product",
    "bbox": [
      179,
      336,
      1000,
      349
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Development Fees hereunder of $1.0 million..",
    "bbox": [
      112,
      369,
      443,
      380
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.2 \"Business Day\"' means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized or",
    "bbox": [
      179,
      384,
      1000,
      397
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "required to be closed in New York City, NY..",
    "bbox": [
      111,
      400,
      432,
      412
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.3 \"Calendar Quarter\"' means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31.",
    "bbox": [
      179,
      417,
      1000,
      428
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.4 \"Confidential Information\"' includes: (1) all information contained in documents marked \"confidential\" and disclosed by one Party (the",
    "bbox": [
      179,
      432,
      1000,
      445
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "\"disclosing party\") to the other Party (the \"recipient party\") pursuant to this Agreement; (2) orally disclosed information which is disclosed by the",
    "bbox": [
      112,
      448,
      1000,
      461
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "disclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as \"confidential\" and delivered to the recipient",
    "bbox": [
      111,
      464,
      1000,
      477
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "party; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person would",
    "bbox": [
      111,
      480,
      1000,
      493
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "treat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not the",
    "bbox": [
      111,
      497,
      1000,
      509
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "information is marked as \"confidential.\" Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNS",
    "bbox": [
      111,
      512,
      1000,
      525
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "determines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof..",
    "bbox": [
      112,
      529,
      1000,
      541
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.5 \"Development Fee'\" means 50% of the Net Sales for any Development Products in the Development Territory..",
    "bbox": [
      179,
      543,
      1000,
      557
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.6 \"Development Products\" means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drug",
    "bbox": [
      180,
      561,
      1000,
      573
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "products for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for the",
    "bbox": [
      112,
      577,
      1000,
      589
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "treatment of any viral infection in humans that is licensed between WPD and MBI after this date..",
    "bbox": [
      112,
      593,
      837,
      604
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.7 \"Development Territory\"' means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense.",
    "bbox": [
      178,
      608,
      1000,
      621
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Agreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland..",
    "bbox": [
      114,
      625,
      1000,
      637
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1",
    "bbox": [
      661,
      648,
      673,
      658
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020",
    "bbox": [
      133,
      1000,
      572,
      1000
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.5 \"Development Fee'\" means 50% of the Net Sales for any Development Products in the Development Territory..",
    "bbox": [
      179,
      543,
      1000,
      557
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  }
]